Oncocross has completed the Phase I global clinical trial of OC514 in Australia for the treatment of sarcopenia and other rare muscular diseases.
SEOUL, South Korea--(BUSINESS WIRE)--Oncocross, a Seoul-based AI drug discovery and development biotech, announced the completion of phase 1 global clinical trial of OC514, a treatment targeting sarcopenia and other rare muscular diseases. Phase 1 was conducted in Australia.